|
KMID : 0368120160460030309
|
|
Korean Circulation Journal
2016 Volume.46 No. 3 p.309 ~ p.314
|
|
|
Antioxidative Activity after Rosuvastatin Treatment in Patients with Stable Ischemic Heart Disease and Decreased High Density Lipoprotein Cholesterol
|
|
Park Do-Sim
Yun Kyeong-Ho
Park Hyun-Young
Rhee Sang-Jae
Kim Nam-Ho
Oh Seok-Kyu
Jeong Jin-Won
|
|
|
Abstract
|
|
|
Background and Objectives: The clinical significance of statin-induced high-density lipoprotein cholesterol (HDL-C) changes is not well known. We investigated whether rosuvastatin-induced HDL-C changes can influence the anti-oxidative action of high-density lipoprotein particle.
Subjects and Methods: A total of 240 patients with stable ischemic heart disease were studied. Anti-oxidative property was assessed by paraoxonase 1 (PON1) activity. We compared the lipid profile and PON1 activity at baseline and at 8 weeks after rosuvastatin 10 mg treatment.
Results: Rosuvastatin treatment increased the mean HDL-C concentration by 1.9±9.2 mg/dL (6.4±21.4%). HDL-C increased in 138 patients (57.5%), but decreased in 102 patients (42.5%) after statin treatment. PON1 activity increased to 19.1% in all patients. In both, the patients with increased HDL-C and with decreased HDL-C, PON1 activity significantly increased after rosuvastatin treatment (+19.3% in increased HDL-C responder; p=0.018, +18.8% in decreased HDL-C responder; p=0.045 by paired t-test). Baseline PON1 activity modestly correlated with HDL-C levels (r=0.248, p=0.009); however, the PON1 activity evaluated during the course of the treatment did not correlate with HDL-C levels (r=0.153, p=0.075).
Conclusion: Rosuvastatin treatment improved the anti-oxidative properties as assessed by PON1 activity, regardless of on-treatment HDL-C levels, in patients with stable ischemic heart disease.
|
|
|
KEYWORD
|
|
|
Hydroxymethylglutaryl-CoA, Reductase inhibitors, High-density lipoproteins, Paraoxonase
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|